MacroGenics, Inc., a biopharmaceutical company concentrating on creating cutting-edge antibody-based therapeutics for cancer treatment, revealed today that its management team will be involved in upcoming investor conferences in March. The company, listed as Nasdaq: MGNX, is based in Rockville, MD, and made the announcement on Feb. 26, 2026.